Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Bayer has developed a successful audience targeting strategy that drives meaningful engagement, with Crossix audience segments optimizing campaigns and aligning messaging more closely with the patient journey. This precision targeting has proven effective in reaching the most qualified audience and increasing engagement.Philips issued a fix for ventilator problems linked to injuries and deaths, Siemens Healthineers received FDA approval for a 3D mammography system, and Synchron's brain-computer interface technology met safety goals. Additionally, the wearables market is expected to see growth, while the FDA missed a target date for releasing rules on pulse oximeters. Medtech Dive provides insights on medical technology trends and top conferences in 2025.A private equity firm, TPG, is set to acquire a majority stake in e-prescribing giant Surescripts. HCA's Mission Hospital in North Carolina faces challenges after Hurricane Helene, while UHS has been forced to pay significant damages related to child sexual abuse allegations. Efforts to combat burnout among healthcare workers are highlighted, along with sponsored content on safeguarding healthcare against cybercrime.Eli Lilly is investing $4.5 billion in a new manufacturing and research center in Indiana, while Amgen faces a class action lawsuit and Johnson & Johnson invests $2 billion in a North Carolina facility. Bayer, J&J, and Pfizer are collectively laying off nearly 500 employees, with new developments in cFDNA methylation assays and royalty financing for biopharma companies. ImmunityBio is also undergoing layoffs in California.Roche is facing an $8 billion sales gap due to biosimilar competition, prompting investments in new blockbuster drugs. Kailera Therapeutics has secured funding for obesity drugs, and the cell and gene therapy industry is experiencing rapid growth. Pharmavoice covers these topics and more in their daily newsletter.2seventy Bio is close to reaching cash flow breakeven, attributing their survival to transparency and a committed staff. Pfizer's withdrawal of sickle cell therapy Oxbryta has raised questions among investors. Royalty financing has become crucial for biopharma companies as traditional fundraising methods falter. Lilly's drug pricing practices are under scrutiny compared to Novo Nordisk. Various updates on investments, layoffs, and legal actions can be found on Biospace's website.